On Jun 29, 2018 Sorrento Therapeutics (NASDAQ:SRNE) with $14.25 Target Was Coveraged By B. Riley FBR.

June 29, 2018 - By Alice Reed

Sorrento Therapeutics, Inc. (NASDAQ:SRNE) Corporate Logo

Big Money Sentiment increased to 5 in Q1 2018. It has change of 3.47, from 2017Q4’s 1.53. The ratio is positive due to Sorrento Therapeutics, Inc. positioning: 2 sold and 7 reduced. 23 funds amassed stakes and 22 increased stakes. Investors holded 8.46 million in 2017Q4 but now own 37.99 million shares or 349.20% more.

Blackrock holds 0% of its capital in Sorrento Therapeutics, Inc. (NASDAQ:SRNE) for 2.19M shs. Element Capital Management Lc holds 0.01% in Sorrento Therapeutics, Inc. (NASDAQ:SRNE) or 68,643 shs. Tci Wealth Advisors invested in 200 shs or 0% of the stock. Connor Clark Lunn Investment Mngmt Limited owns 118,685 shs. Bluecrest Management accumulated 282,795 shs. Tower Rech Limited Liability Corporation (Trc) holds 0% or 100 shs. Lucas Mgmt, a New Jersey-based fund reported 23,000 shs. Glenmede Na accumulated 29,135 shs. Texas-based Dimensional Fund Advisors Lp has invested 0% in Sorrento Therapeutics, Inc. (NASDAQ:SRNE). Gsa Capital Ptnrs Ltd Liability Partnership holds 235,495 shs. Gotham Asset Mgmt Ltd Liability Com stated it has 0.01% of its capital in Sorrento Therapeutics, Inc. (NASDAQ:SRNE). California Employees Retirement invested in 0% or 36,800 shs. Barclays Plc has invested 0% of its capital in Sorrento Therapeutics, Inc. (NASDAQ:SRNE). Virtu Finance Ltd Liability Corp has invested 0.01% in Sorrento Therapeutics, Inc. (NASDAQ:SRNE). Susquehanna Group Llp stated it has 0% of its capital in Sorrento Therapeutics, Inc. (NASDAQ:SRNE).

Sorrento Therapeutics, Inc. had 4 selling transactions and 2 buys since January 23, 2018. This’s net activity of $11.11 million. 64,600 shs were bought by Ji Henry, worth $642,770. 684,288 shs were sold by Asia Pacific MedTech (BVI) Ltd, worth $5.18 million. Ng George K had bought 90,000 shs worth $895,500.

What Price Target Has B. Riley FBR Given Sorrento Therapeutics (NASDAQ:SRNE)

Professional analysts at B. Riley FBR gave “Buy” rating and has TP of $14.25 on SRNE’s shares. On 28 June a coverage initiated with Sorrento Therapeutics (NASDAQ:SRNE)‘s stock.

Sorrento Therapeutics, Inc. (NASDAQ:SRNE) Ratings Coverage

In total 3 analysts cover Sorrento Therapeutics (NASDAQ:SRNE). “Buy” rating has 3, “Sell” are 0, while 0 are “Hold”. 100% are bullish. 13 are the (NASDAQ:SRNE)’s analyst reports since January 19, 2018 according to StockzIntelligence Inc. On Thursday, March 1 Oppenheimer maintained the shares of SRNE in report with “Buy” rating. On Monday, June 11 the firm has “Buy” rating by H.C. Wainwright given. On Tuesday, February 20 the stock of Sorrento Therapeutics, Inc. (NASDAQ:SRNE) has “Buy” rating given by H.C. Wainwright. In Tuesday, March 6 report H.C. Wainwright maintained the stock with “Buy” rating. On Thursday, April 12 the rating was maintained by H.C. Wainwright with “Buy”. On Friday, January 19 the company was maintained by Oppenheimer. The stock rating was maintained by H.C. Wainwright with “Buy” on Thursday, February 1. On Tuesday, January 23 the stock of Sorrento Therapeutics, Inc. (NASDAQ:SRNE) has “Buy” rating given by H.C. Wainwright. On Tuesday, April 3 the rating was maintained by H.C. Wainwright with “Buy”. On Friday, April 6 Oppenheimer maintained Sorrento Therapeutics, Inc. (NASDAQ:SRNE) rating. Oppenheimer has “Buy” rating and $1000 target.

Ticker’s shares touched $7.15 during the last trading session after 0.69% change.Sorrento Therapeutics, Inc. has volume of 474,802 shares. Since June 29, 2017 SRNE has risen 375.76% and is uptrending. SRNE outperformed the S&P500 by 363.19%.

Sorrento Therapeutics, Inc., a clinical stage biotechnology company, primarily engages in the discovery and development of therapies focused on oncology and the treatment of chronic cancer pain worldwide.The firm is worth $771.69 million. The firm is focusing on the development of chimeric antigen receptor immunotherapies using autologous T-cells.55 is the P/E ratio. It is developing CD38 Directed CAR-T, a cellular therapy used for the treatment of multiple myeloma, as well as for amyloidosis and graft-versus-host diseases; CD123 Directed CAR-T for the treatment of acute myelogenous leukemia; and human antibodies, including PD-1, PD-L1, CD38, CD123, CD47, c-MET, VEGFR2, CCR2, OX40, TIGIT, and CD137.

Another two news for Sorrento Therapeutics, Inc. (NASDAQ:SRNE) were briefly brought out by: Benzinga.com on June 27, 2018 with title “54 Biggest Movers From Yesterday”. The other Globenewswire.com‘s article was titled “Sorrento Therapeutics issues Chairman/CEO corporate update to stockholders” and brought out on June 14, 2018.

Sorrento Therapeutics, Inc. (NASDAQ:SRNE) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.